These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

572 related items for PubMed ID: 15225108

  • 1. Losartan in diabetic nephropathy.
    Perico N, Ruggenenti P, Remuzzi G.
    Expert Rev Cardiovasc Ther; 2004 Jul; 2(4):473-83. PubMed ID: 15225108
    [Abstract] [Full Text] [Related]

  • 2. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options.
    Sica DA, Bakris GL.
    J Clin Hypertens (Greenwich); 2002 Jul; 4(1):52-7. PubMed ID: 11821641
    [Abstract] [Full Text] [Related]

  • 3. The pleiotropic effects of angiotensin receptor blockers.
    Chrysant SG, Chrysant GS.
    J Clin Hypertens (Greenwich); 2006 Apr; 8(4):261-8. PubMed ID: 16596029
    [Abstract] [Full Text] [Related]

  • 4. Intensive diabetes management for high-risk patients: how best to deliver?
    Marshall SM.
    Diabetes Care; 2009 Jun; 32(6):1132-3. PubMed ID: 19460918
    [No Abstract] [Full Text] [Related]

  • 5. Number and frequency of albuminuria measurements in clinical trials in diabetic nephropathy.
    Kröpelin TF, de Zeeuw D, Andress DL, Bijlsma MJ, Persson F, Parving HH, Heerspink HJ.
    Clin J Am Soc Nephrol; 2015 Mar 06; 10(3):410-6. PubMed ID: 25568217
    [Abstract] [Full Text] [Related]

  • 6. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence.
    Bakris GL, Weir M.
    J Clin Hypertens (Greenwich); 2002 Mar 06; 4(6):420-3. PubMed ID: 12461306
    [Abstract] [Full Text] [Related]

  • 7. Early diabetic nephropathy in type 1 diabetes: new insights.
    Bjornstad P, Cherney D, Maahs DM.
    Curr Opin Endocrinol Diabetes Obes; 2014 Aug 06; 21(4):279-86. PubMed ID: 24983394
    [Abstract] [Full Text] [Related]

  • 8. Therapeutic modalities in diabetic nephropathy: standard and emerging approaches.
    Abdel-Rahman EM, Saadulla L, Reeves WB, Awad AS.
    J Gen Intern Med; 2012 Apr 06; 27(4):458-68. PubMed ID: 22005942
    [Abstract] [Full Text] [Related]

  • 9. Renoprotection and the Bardoxolone Methyl Story - Is This the Right Way Forward? A Novel View of Renoprotection in CKD Trials: A New Classification Scheme for Renoprotective Agents.
    Onuigbo M.
    Nephron Extra; 2013 Jan 06; 3(1):36-49. PubMed ID: 23687511
    [Abstract] [Full Text] [Related]

  • 10. Creatinine excretion rate and mortality in type 2 diabetes and nephropathy.
    Sinkeler SJ, Kwakernaak AJ, Bakker SJ, Shahinfar S, Esmatjes E, de Zeeuw D, Navis G, Lambers Heerspink HJ.
    Diabetes Care; 2013 Jun 06; 36(6):1489-94. PubMed ID: 23300289
    [Abstract] [Full Text] [Related]

  • 11. Statin therapy for patients with diabetic nephropathy: balance between safety and efficacy of statin treatment for patients with impaired kidney function.
    Jairoun AA, Ping CC, Ibrahim B.
    Eur Rev Med Pharmacol Sci; 2023 Nov 06; 27(21):10595-10604. PubMed ID: 37975384
    [Abstract] [Full Text] [Related]

  • 12. Inhibition of RAS in diabetic nephropathy.
    Yacoub R, Campbell KN.
    Int J Nephrol Renovasc Dis; 2015 Nov 06; 8():29-40. PubMed ID: 25926752
    [Abstract] [Full Text] [Related]

  • 13. You are what you eat: dietary salt intake and renin-angiotensin blockade in diabetic nephropathy.
    Charytan DM, Forman JP.
    Kidney Int; 2012 Aug 06; 82(3):257-9. PubMed ID: 22791321
    [Abstract] [Full Text] [Related]

  • 14. Emerging therapies for diabetic nephropathy patients: beyond blockade of the Renin-Angiotensin system.
    Tanios BY, Ziyadeh FN.
    Nephron Extra; 2012 Jan 06; 2(1):278-82. PubMed ID: 23599705
    [Abstract] [Full Text] [Related]

  • 15. Diabetic nephropathy.
    Harvey JN.
    BMJ; 2002 Jul 13; 325(7355):59-60. PubMed ID: 12114223
    [No Abstract] [Full Text] [Related]

  • 16. Sparsentan is superior to losartan in the gddY mouse model of IgA nephropathy.
    Nagasawa H, Ueda S, Suzuki H, Jenkinson C, Fukao Y, Nakayama M, Otsuka T, Okuma T, Clapper W, Liu K, Nguyen M, Komers R, Suzuki Y.
    Nephrol Dial Transplant; 2024 Jan 25. PubMed ID: 38271614
    [Abstract] [Full Text] [Related]

  • 17. Time to re-evaluate effects of renin-angiotensin system inhibitors on renal and cardiovascular outcomes in diabetic nephropathy.
    Suzuki H, Kikuta T, Inoue T, Hamada U.
    World J Nephrol; 2015 Feb 06; 4(1):118-26. PubMed ID: 25664254
    [Abstract] [Full Text] [Related]

  • 18. Can existing drugs approved for other indications retard renal function decline in patients with type 1 diabetes and nephropathy?
    Doria A, Niewczas MA, Fiorina P.
    Semin Nephrol; 2012 Sep 06; 32(5):437-44. PubMed ID: 23062984
    [Abstract] [Full Text] [Related]

  • 19. Is clinical trial data showing positive progress for the treatment of diabetic kidney disease?
    Tan SK, Cooper ME.
    Expert Opin Emerg Drugs; 2023 Dec 06; 28(4):217-226. PubMed ID: 37897430
    [No Abstract] [Full Text] [Related]

  • 20. Sixty Years of Confronting Diabetes and Kidney Disease.
    Luft FC.
    Semin Nephrol; 2023 May 06; 43(3):151426. PubMed ID: 37862743
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.